ABSTRACT

A low toxicity, stable oxazaphosphorine containing compositions with mesna for parenteral administration has been described. The process essentially requires addition of an oxazaphosphorine antineoplastic to the aqueous solution of an etherified β-cyclodextrin followed by addition of mesna as such or as an aqueous solution containing optionally, an etherified β-cyclodextrin. Preferably, the oxazaphosphorine antineoplastic is Ifosfamide and the etherified β-cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.